Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy.
Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans
Administration. It is a randomized control format including genotypes 1 and 3. There will
also be pilot arms for HCV carriers who present for screening already on a statin, who will
be allowed to stay on their current statin or switched to another statin. In all ways,
standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package
insert.
Phase:
Phase 2
Details
Lead Sponsor:
Bader, Ted, M.D.
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development